A61P 5/50
For increasing or potentiating the activity of insulin
Official title: for increasing or potentiating the activity of insulin
A61P5/50 (For increasing or potentiating the activity of insulin) appears on 2,033 US grants and 3,216 published applications in this corpus.
Search patents in A61P- Granted patents
- 2,033
- Published applications
- 3,216
- Assignees
- 1,074
- Inventors
- 5,682
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 3 | 0 |
| 1997 | 3 | 0 |
| 1998 | 6 | 0 |
| 1999 | 17 | 0 |
| 2000 | 18 | 0 |
| 2001 | 49 | 12 |
| 2002 | 32 | 61 |
| 2003 | 37 | 79 |
| 2004 | 27 | 130 |
| 2005 | 33 | 122 |
| 2006 | 50 | 130 |
| 2007 | 48 | 168 |
| 2008 | 67 | 157 |
| 2009 | 72 | 234 |
| 2010 | 126 | 248 |
| 2011 | 116 | 227 |
| 2012 | 146 | 190 |
| 2013 | 177 | 174 |
| 2014 | 157 | 179 |
| 2015 | 154 | 172 |
| 2016 | 113 | 152 |
| 2017 | 141 | 144 |
| 2018 | 96 | 107 |
| 2019 | 87 | 116 |
| 2020 | 71 | 104 |
| 2021 | 56 | 80 |
| 2022 | 38 | 61 |
| 2023 | 25 | 46 |
| 2024 | 29 | 47 |
| 2025 | 26 | 48 |
| 2026 | 8 | 28 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Focal adhesion kinase inhibitor as a therapeutic agent in diabetes11 Aug 2026US 12,702,667 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Compositions comprising miR-690 and methods therefor16 Jun 2026US 12,653,783 B2The Regents of the University of California
- Bifidobacteria for treating diabetes and related conditions7 Apr 2026US 12,594,309 B2International N&H Denmark Aps
- Activin receptor type IIA variants and methods of use thereof24 Mar 2026US 12,582,700 B2Keros Therapeutics, Inc.
- Insulin preparations containing methionine24 Feb 2026US 12,558,307 B2Sanofi-Aventis
- Use of composition containing candesartan or azilsartan10 Sep 2026US 2026/0263425 A1Gachon University of Industry-Academic Cooperation Foundation
- Combination of beta-2-adrenergic receptor agonists and glp-1 receptor agonists for use in treating hyperglycaemia3 Sep 2026US 2026/0256751 A1Atrogi AB
- Heterotrimer g-receptor agonist composition, and uses thereof27 Aug 2026US 2026/0248867 A1MOF Science, LLC
- AMPK Activator Containing 1,1-diethoxyethane as an Active Ingredient and Its Use20 Aug 2026US 2026/0240790 A1Lux Anima Co., Ltd.
- Targeted reduction of cd59 for use in treating disease13 Aug 2026US 2026/0234637 A1Cumbara Biotechnologies Ltd
Most cited
By later US patents
- Methods and compositions for pulmonary delivery of insulin246US 5,997,848 AInhale Therapeutic Systems · 1999
- Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals233US 6,303,661 B1Probiodrug AG · 2001
- Use of GLP-1 or analogs to abolish catabolic changes after surgery230US 6,006,753 AEli Lilly and Company · 1999
- Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same222US 5,359,030 AProtein Delivery, Inc. · 1994
- Therapeutic preparation for inhalation202US 5,518,998 AAstra AB · 1996